Programs
Putting our science into action
Our research programs
VCAR33ALLO
VCAR33ALLO is manufactured from lymphocytes collected from the patient’s original transplant donor, generating a CAR-T cell therapy that is exactly matched to the recipient’s engrafted blood system.
Trem-cel
Trem-cel (tremtelectogene empogeditemcel) is a shielded transplant in development for patients with AML, in which healthy transplant donor cells are genetically engineered by removing CD33, with the potential to enable targeted therapies such as Mylotarg and CD33-targeted CAR-T therapy post-transplant, while avoiding on-target toxicities.
Treatment systems
TREM-CEL + VCAR33 treatment system
Trem-cel + VCAR33 Treatment System is a novel and comprehensive approach that has the potential to transform clinical outcomes and establish a new standard of care for patients suffering with AML.
CD33-CLL1 Multiplex treatment system
This Treatment System would remove multiple surface targets in eHSCs and use a multi-specific CAR-T.
Discovery platform
We are conducting ongoing discovery efforts in commonly transplanted hematologic malignancies.
We operate an in-house clinical manufacturing facility in Cambridge, Massachusetts to support development of our shielded transplants and CAR-T therapeutic candidates for patients with blood cancers.